1994 Fiscal Year Final Research Report Summary
Mechanism of megakaryocytic differentiation Enhancement of thrombopoietic activity by stromal cells
Project/Area Number |
05670189
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Experimental pathology
|
Research Institution | University of Tokyo |
Principal Investigator |
TANGE Tsuyoshi University of Tokyo, Faculty of Medicine Pathology Lecturer, 医学部(医), 講師 (10107667)
|
Project Period (FY) |
1993 – 1994
|
Keywords | megakaryocyte / differentiation / thrombopoietin / stromal cell / proplatelet / PPF / IL-6 / IL-11 |
Research Abstract |
1. Rat megakaryocytes (MK) were isolated by an immunomagnetic beads method as described in the report of last year. Then, IL-6 and IL-11 were compared for PPF activity because they are known to be pluripotent factors having many similarities in biological aspects although they are categolized as a MK-potentiator (Meg-POT). As a result of it, IL-11 was wuite different in the PPF activity from IL-6 because IL-11 alone is ineffective at 0.01 to 100ng/ml for the PPF activity and not synergistic to erythropoietin (Epo), and slightly effective in the coculture system of MK and stromal cells (fibroblasts), while IL-6 was remarkably effective in all cases. 2. A novel factor, a ligand for c-Mpl, is thought to be thrombopoietin (TPO). TPO delivered from Kirin Brewery Co. Ltd. was compared with IL-6 and Epo for the PPF activity in the same way. In serum-free PPF assay, TPO was strongly (100-1,000 fold) effective because the effective doses of TPO ranged from 0.00001 to 1ng/ml and effective reange was expanded up to 100ng/ml in the coculture system using porcine endothelial cells, in which the PPF activity (score of PPF) of TPO as well as IL-6 and Epo was greatly enhanced. The effective doses of IL-6 and Epo are from 0.1 to 100ng/ml and 0.01 to 10U.ml respectively.
|